Bone remodeling is characterized by spatial and temporal coupling of bone resorption and formation and is necessary for skeletal growth and normal bone structure maintenance. Imbalance of this process is related to metabolic bone disorders such as osteoporosis or rheumatoid arthritis. For this reason, bone remodeling is under the control of several local and systemic factors, including molecules of the immune system. The importance of the interplay of both the skeletal and immune systems is reflected by the emerging interdisciplinary research field, called osteoimmunology, focused on common aspects of osteology and immunology. This review focuses on the role of inflammatory mediators, such as cytokines in bone remodeling and, in particular, a subfamily of chemotactic cytokines or chemokines which are involved not only in several aspects of physiological bone remodeling but also in pathological bone disorders, such as rheumatoid arthritis or osteoporosis. Understanding the role of inflammation and chemokines will provide new insights for the treatment of diseases affecting both skeletal and immune systems, by the development of new therapeutic strategies targeting common inflammatory mediators.
TakayanagiH. Inflammatory bone destruction and osteoimmunology. J Periodontal Res2005; 40:287–93.
5.
TakayanagiH. Introduction to osteoimmunology. Nippon Rinsho2005; 63:1505–9.
6.
GoltzmanDMiaoDPandaDKHendyGN. Effects of calcium and of the Vitamin D system on skeletal and calcium homeostasis: lessons from genetic models. J Steroid Biochem Mol Biol2004; 89:485–9.
7.
ArronJRChoiY. Bone versus immune system. Nature2000; 408:535–6.
8.
WalshMCKimNKadonoY. Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol2006; 24:33–63.
9.
MiyamotoTAraiFOhnedaOTakagiKAndersonDMSudaT. An adherent condition is required for formation of multinuclear osteoclasts in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor kappa B ligand. Blood2000; 96:4335–43.
10.
SimonetWSLaceyDLDunstanCR. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell1997; 89:309–19.
11.
GingeryABradleyEShawAOurslerMJ. Phosphatidylinositol 3-kinase coordinately activates the MEK/ERK and AKT/NFkappaB pathways to maintain osteoclast survival. J Cell Biochem2003; 89:165–79.
12.
MatsumotoMSudoTSaitoTOsadaHTsujimotoM. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J Biol Chem2000; 275(311)55–61.
13.
WittrantYTheoleyreSCouillaudSDunstanCHeymannDRediniF. Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities. Exp Cell Res2004; 293:292–301.
14.
DejanaEJi-MingWMantovaniA. The recruitment of leukocytes and their interaction with the vessel wall: the role of interleukin-1 and tumor necrosis factor. Scand J Rheumatol Suppl1987; 66:19–25.
KobayashiKTakahashiNJimiE. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med2000; 191:275–86.
17.
StashenkoPDewhirstFEPerosWJKentRLAgoJM. Synergistic interactions between interleukin 1, tumor necrosis factor, and lymphotoxin in bone resorption. J Immunol1987; 138:1464–8.
18.
SudaTTakahashiNUdagawaNJimiEGillespieMTMartinTJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev1999; 20:345–57.
19.
HofbauerLCLaceyDLDunstanCRSpelsbergTCRiggsBLKhoslaS. Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone1999; 25:255–9.
20.
SatoKFujiiYAsanoS. Recombinant human interleukin 1 alpha and beta stimulate mouse osteoblast-like cells (MC3T3-E1) to produce macrophage-colony stimulating activity and prostaglandin E2. Biochem Biophys Res Commun1986; 141:285–91.
21.
KleinDCRaiszLG. Prostaglandins: stimulation of bone resorption in tissue culture. Endocrinology1970; 86:1436–40.
22.
IshimiYMiyauraCJinCH. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol1990; 145:3297–303.
23.
GirasoleGJilkaRLPasseriG. 17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest1992; 89:883–91.
24.
RoodmanGDKuriharaNOhsakiY. Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone. J Clin Invest1992; 89:46–52.
25.
YamamotoTOzonoKKasayamaS. Increased IL-6-production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright syndrome. J Clin Invest1996; 98:30–5.
26.
ReddySVTakahashiSDallasMWilliamsRENeckersLRoodmanGD. Interleukin-6 antisense deoxyoligonucleotides inhibit bone resorption by giant cells from human giant cell tumors of bone. J Bone Miner Res1994; 9:753–7.
27.
OpdenakkerGVan DammeJ. Cytokines and proteases in invasive processes: molecular similarities between inflammation and cancer. Cytokine1992; 4:251–8.
28.
Van DammeJProostPLenaertsJPOpdenakkerG. Structural and functional identification of two human, tumor-derived monocyte chemotactic proteins (MCP-2 and MCP-3) belonging to the chemokine family. J Exp Med1992; 176:59–65.
29.
RahimiPWangCYStashenkoPLeeSKLorenzoJAGravesDT. Monocyte chemoattractant protein-1 expression and monocyte recruitment in osseous inflammation in the mouse. Endocrinology1995; 136:2752–9.
30.
GravesDTJiangYValenteAJ. The expression of monocyte chemoattractant protein-1 and other chemokines by osteoblasts. Front Biosci1999; 4:571–80.
31.
JiangYGravesDT. Periodontal pathogens stimulate CC-chemokine production by mononuclear and bone-derived cells. J Periodontol1999; 70:1472–8.
32.
KukitaTKukitaAHaradaHIijimaT. Regulation of osteoclastogenesis by antisense oligodeoxynucleotides specific to zinc finger nuclear transcription factors Egr-1 and WT1 in rat bone marrow culture system. Endocrinology1997; 138:4384–9.
33.
YangMMailhotGMacKayCAMason-SavasAAubinJOdgrenPR. Chemokine and chemokine receptor expression during colony stimulating factor-1-induced osteoclast differentiation in the toothless osteopetrotic rat: a key role for CCL9 (MIP-1 gamma) in osteoclastogenesis in vivo and in vitro. Blood2006; 107:2262–70.
34.
LeanJMMurphyCFullerKChambersTJ. CCL9/MIP-1gamma and its receptor CCR1 are the major chemokine ligand/receptor species expressed by osteoclasts. J Cell Biochem2002; 87:386–93.
GronthosSZannettinoAC. The role of the chemokine CXCL12 in osteoclastogenesis. Trends Endocrinol Metab2007; 18:108–13.
37.
NagasawaTTachibanaKKishimotoT. Anovel CXC chemokine PBSF/SDF-1 and its receptor CXCR4: their functions in development, hematopoiesis and HIV infection. Semin Immunol1998; 10:179–85.
38.
TachibanaKHirotaSIizasaH. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature1998; 393:591–4.
39.
LevesqueJPHendyJTakamatsuYSimmonsPJBendallLJ. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest2003; 111:187–96.
40.
PetitISzyper-KravitzMNaglerA. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol2002; 3:687–94.
41.
KortesidisAZannettinoAIsenmannSShiSLapidotTGronthosS. Stromal-derived factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cells. Blood2005; 105:3793–801.
42.
WrightLMMaloneyWYuXKindleLCollin-OsdobyPOsdobyP. Stromal cell-derived factor-1 binding to its chemokine receptor CXCR4 on precursor cells promotes the chemotactic recruitment, development and survival of human osteoclasts. Bone2005; 36:840–53.
43.
YuXHuangYCollin-OsdobyPOsdobyP. Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration. J Bone Miner Res2003; 18:1404–18.
44.
ChinniSRSivaloganSDongZ. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate2006; 66:32–48.
45.
StrahmBDurbinADSexsmithEMalkinD. The CXCR4-SDF1alpha axis is a critical mediator of rhabdomyosarcoma metastatic signaling induced by bone marrow stroma. Clin Exp Metastasis2008; 25:110.
46.
SunYXSchneiderAJungY. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res2005; 20:318–29.
47.
LisignoliGPiacentiniAToneguzziS. Age-associated changes in functional response to CXCR3 and CXCR5 chemokine receptors in human osteoblasts. Biogerontology2003; 4(5):309–17.
48.
LisignoliGToneguzziSPiacentiniA. Human osteoblasts express functional CXC chemokine receptors 3 and 5: activation by their ligands, CXCL10 and CXCL13, significantly induces alkaline phosphatase and beta-N-acetylhexosaminidase release. J Cell Physiol2003; 194:71–9.
49.
LisignoliGToneguzziSPiacentiniA. CXCL12 (SDF-1) and CXCL13 (BCA-1) chemokines significantly induce proliferation and collagen type I expression in osteoblasts from osteoarthritis patients. J Cell Physiol2006; 206:78–85.
50.
RoodmanGD. Biology of osteoclast activation in cancer. J Clin Oncol2001; 19(15):3562–71.
MainiRNFeldmannM. Cytokine therapy in rheumatoid arthritis. Lancet1996; 348:824–5.
53.
LisignoliGToneguzziSGrassiF. Different chemokines are expressed in human arthritic bone biopsies: IFN-gamma and IL-6 differently modulate IL-8, MCP-1 and rantes production by arthritic osteoblasts. Cytokine2002; 20:231–8.
54.
CristinoSPiacentiniAManferdiniC. Expression of CXC chemokines and their receptors is modulated during chondrogenic differentiation of human mesenchymal stem cells grown in three-dimensional scaffold: evidence in native cartilage. Tissue Eng2007; (Epub ahead of print).
55.
LisignoliGPiacentiniACristinoS. CCL20 chemokine induces both osteoblast proliferation and osteoclast differentiation: Increased levels of CCL20 are expressed in subchondral bone tissue of rheumatoid arthritis patients. J Cell Physiol2007; 210:798–806.
56.
MundyGR. Cellular and molecular regulation of bone turnover. Bone1999; 24(S):35–38.
57.
NakayamaTHieshimaKIzawaDTatsumiYKanamaruAYoshieO. Cutting edge: profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J Immunol2003; 170:1136–40.
58.
HanJHChoiSJKuriharaNKoideMObaYRoodmanGD. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood2001; 97:3349–53.
59.
De KlerckBGeboesLHatseS. Proinflammatory properties of stromal cell-derived factor-1 (CXCL 12) in collagen-induced arthritis. Arthritis Res Ther2005; 7:1208–20.
60.
ZannettinoACFarrugiaANKortesidisA. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res2005; 65:1700–9.
